Journal of the Korean Association of Oral and Maxillofacial Surgeons

  • 제29권6호
  • /
  • Pages.365-373
  • /
  • 2003
  • /
  • 2234-7550(pISSN)
  • /
  • 2234-5930(eISSN)
대한구강악안면외과학회 (The Korean Association of Oral and Maxillofacial Surgeons)
권호 표지

구강암세포주에서의 Tamoxifen의 항암효과

ANTICANCER EFFECT OF TAMOXIFEN IN ORAL CANCER CELL

  • 정재화 (서울대학교 치과대학 구강악안면외과학교실) ;
  • 윤필영 (서울대학교 치과대학 구강악안면외과학교실) ;
  • 명훈 (서울대학교 치과대학 구강악안면외과학교실) ;
  • 신재일 (서울대학교 치과대학 구강악안면외과학교실) ;
  • 이종호 (서울대학교 치과대학 구강악안면외과학교실) ;
  • 김명진 (서울대학교 치과대학 구강악안면외과학교실)
  • Jung, Jae-Hwa (Department of Oral and Maxillofacial Surgery, College of Dentistry, Seoul National University) ;
  • Yun, Pil-Young (Department of Oral and Maxillofacial Surgery, College of Dentistry, Seoul National University) ;
  • Myoung, Hoon (Department of Oral and Maxillofacial Surgery, College of Dentistry, Seoul National University) ;
  • Shin, Jae-Il (Department of Oral and Maxillofacial Surgery, College of Dentistry, Seoul National University) ;
  • Lee, Jong-Ho (Department of Oral and Maxillofacial Surgery, College of Dentistry, Seoul National University) ;
  • Kim, Myung-Jin (Department of Oral and Maxillofacial Surgery, College of Dentistry, Seoul National University)
  • 발행 : 2003.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Tamoxifen is an selective estrogen receptor antagonist widely used in the management of patients with breast cancer for more than 30 years. It was thought to act primarily through occupying the estrogen receptor sites in ER positive breast cancer cells and directly on cancer cell proper. These inhibitory effects, which have been shown to be independent of the ER, highlight new mechanism of therapeutic action of tamoxifen. The purposes of this study were to identify ER in oral carcinoma cell lines and to evaluate ER independent cytotoxic effect of tamoxifen. KB(SCC), HSC-3(SCC) and A253(ACC) cell line were used and capacity of cell proliferation, apoptosis, in vitro invasion and gelatin zymography were tested. ER expression of each cell line were detected by RT-PCR and immunocytochemistry. Dose dependent inhibition of cell proliferation and inhibition of gelatinolytic activity were observed in all oral carcinoma cell lines and significant difference of apoptotic index were observed in A253 and KB. Tamoxifen inhibited in vitro invasion in all experimental groups. ER expression was detected in KB and A253. These data suggest that tamoxifen may play a role in management of oral carcinoma by independent cytotoxic effect and more advanced research must processed confirming ER-dependent cytotoxicity.

키워드

참고문헌

  1. Klein-Hitpass L, Ryffel GU, Heitlinger E, Cato AC. A 13 bp palindrome is a functional estrogen responsive element and interacts specifically with estrogen receptor. Nucleic Acids Res. 1988 Jan 25;16(2):647-63.
  2. Hyder SM, Stancel GM. In vitro interaction of uterine estrogen receptor with the estrogen response element present in the 3'-flanking region of the murine c-fos protooncogene. J Steroid Biochem Mol Biol. 1994 Jan;48(1):69-79.
  3. Hyder SM, Nawaz Z, Chiappetta C, Stancel GM. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res. 2000 Jun 15;60(12):3183-90.
  4. Cowley SM, Parker MG. A comparison of transcriptional activation by ER alpha and ER beta. J Steroid Biochem Mol Biol. 1999 Apr-Jun;69(1-6):165-75.
  5. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995 May;146(5):1029-39. Review.
  6. Rak J, Filmus J, Kerbel RS. Reciprocal paracrine interactions between tumour cells and endothelial cells: the 'angiogenesis progression' hypothesis. Eur J Cancer. 1996 Dec;32A(14):2438-50. Review.
  7. Shen F, Xue X, Weber G. Tamoxifen and genistein synergistically down-regulate signal transduction and proliferation in estrogen receptor-negative human breast carcinoma MDA-MB-435 cells. Anticancer Res. 1999 May-Jun;19(3A):1657-62.
  8. Charlier C, Chariot A, Antoine N, Merville MP, Gielen J, Castronovo V. Tamoxifen and its active metabolite inhibit growth of estrogen receptor-negative MDA-MB-435 cells. Biochem Pharmacol. 1995 Jan 31;49(3):351-8.
  9. Perry RR, Kang Y, Greaves B. Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells. Ann Surg Oncol. 1995 May;2(3):238-45.
  10. Ro JY, Silva EG, Gallager HS. Adenoid cystic carcinoma of the breast. Hum Pathol. 1987 Dec;18(12):1276-81. Review.
  11. Schmitt FC, Zelandi Filho C, Bacchi MM, Castilho ED, Bacchi CE. Adenoid cystic carcinoma of trachea metastatic to the placenta. Hum Pathol. 1989 Feb;20(2):193-5.
  12. Aldous WK, Marean AJ, DeHart MJ, Matej LA, Moore KH. Effects of tamoxifen on telomerase activity in breast carcinoma cell lines. Cancer. 1999 Apr 1;85(7):1523-9.
  13. Anolik JH, Klinge CM, Brolly CL, Bambara RA, Hilf R. Stability of the ligand-estrogen receptor interaction depends on estrogen response element flanking sequences and cellular factors. J Steroid Biochem Mol Biol. 1996 Dec;59(5-6):413-29.
  14. Hyder SM, Stancel GM, Nawaz Z, McDonnell DP, Loose-Mitchell DS. Identification of an estrogen response element in the 3'-flanking region of the murine c-fos protooncogene. J Biol Chem. 1992 Sep 5;267(25):18047-54.
  15. Altan N, Chen Y, Schindler M, Simon SM. Tamoxifen inhibits acidification in cells independent of the estrogen receptor. Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4432-7.
  16. Levine AC, Liu XH, Greenberg PD, Eliashvili M, Schiff JD, Aaronson SA, Holland JF, Kirschenbaum A. Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts. Endocrinology. 1998 Nov;139(11):4672-8.
  17. Santin AD, Hermonat PL, Ravaggi A, Cannon MJ, Pecorelli S, Parham GP. Secretion of vascular endothelial growth factor in ovarian cancer. Eur J Gynaecol Oncol. 1999;20(3):177-81.
  18. Farinati F, De Maria N, Fornasiero A, Salvagnini M, Fagiuoli S, Chiaramonte M, Naccarato R. Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma. Dig Dis Sci. 1992 May;37(5):659-62.
  19. Wada T, Nishiyama K, Maeda M, Hara S, Tanaka N, Yasutomi M, Kurita T. Combined chemoendocrine treatment with tegafur and tamoxifen for advanced renal cell carcinoma. Anticancer Res. 1995 Jul-Aug;15(4):1581-4.
  20. Charlier C, Chariot A, Antoine N, Merville MP, Gielen J, Castronovo V. Tamoxifen and its active metabolite inhibit growth of estrogen receptor-negative MDA-MB-435 cells. Biochem Pharmacol. 1995 Jan 31;49(3):351-8.
  21. Hoelting T, Siperstein AE, Duh QY, Clark OH. Tamoxifen inhibits growth, migration, and invasion of human follicular and papillary thyroid cancer cells in vitro and in vivo. J Clin Endocrinol Metab. 1995 Jan;80(1):308-13.
  22. Mullauer L, Grasl-Kraupp B, Bursch W, Schulte-Hermann R. Transforming growth factor beta 1-induced cell death in preneoplastic foci of rat liver and sensitization by the antiestrogen tamoxifen. Hepatology. 1996 Apr;23(4):840-7.
  23. Auerbach W, Auerbach R.Angiogenesis inhibition: a review. Pharmacol Ther. 1994 Sep;63(3):265-311. Review.
  24. Engstrom PF, Levin B, Moertel CG, Schutt A. A phase II trial of tamoxifen in hepatocellular carcinoma. Cancer. 1990 Jun 15;65(12):2641-3.
  25. Wiseman H. Tamoxifen: new membrane-mediated mechanisms of action and therapeutic advances. Trends Pharmacol Sci. 1994 Mar;15(3):83-9. Review.
  26. Shadaba A, Gaze MN, Grant HR. The response of adenoid cystic carcinoma to tamoxifen. J Laryngol Otol. 1997 Dec;111(12):1186-9.
  27. Shick PC, Riordan GP, Foss RD. Estrogen and progesterone receptors in salivary gland adenoid cystic carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995 Oct;80(4):440-4.
  28. Fan CY, Wang J, Barnes EL. Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature. Am J Surg Pathol. 2000 Apr;24(4):579-86. https://doi.org/10.1097/00000478-200004000-00014
  29. Werner A, Bender E, Mahaffey W, McKeating J, Marrangoni A, Katoh A. Inhibition of experimental liver metastasis by combined treatment with tamoxifen and interferon. Anticancer Drugs. 1996 May;7(3):307-11.
  30. Tsai LC, Hung MW, Yuan CC, Chao PL, Jiang SY, Chang GG, Chang TC. Effects of tamoxifen and retinoic acid on cell growth and c-myc gene expression in human breast and cervical cancer cells. Anticancer Res. 1997 Nov-Dec;17(6D):4557-62.